Evidence map›Paper›PMID 34623943›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Meeting the Challenges in Cancer Care Management During the SARS-Cov-2 Pandemic: A Retrospective Analysis.

Marika Rasschaert, Pieterjan Vanclooster, Laura Depauw, Tim Mertens, Ella Roelant, Elke Coenen, Sebastien Anguille, Annelies Janssens, Peter Van Dam, Marc Peeters

Open access · goldAbstract read
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Marika RasschaertDepartment of Oncology, 60202Antwerp University Hospital Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0003-3051-6481
Pieterjan VancloosterDepartment of Oncology, 60202Antwerp University Hospital Antwerp, Antwerp, Belgium.
Laura DepauwDepartment of Oncology, 60202Antwerp University Hospital Antwerp, Antwerp, Belgium.
Tim MertensDepartment of Oncology, 60202Antwerp University Hospital Antwerp, Antwerp, Belgium.
Ella RoelantClinical Trials Center (CTC), CRC Antwerp, 60202Antwerp University Hospital, Antwerp, Belgium.
Elke CoenenDepartment of Occupational Medicine, 60202Antwerp University Hospital, Antwerp, Belgium.
Sebastien AnguilleDepartment of Hematology, 60202Antwerp University Hospital, Antwerp, Belgium.
Annelies JanssensDepartment of Thoracic Oncology, 60202Antwerp University Hospital, Antwerp, Belgium.
Peter Van DamUnit of Gynecologic Oncology, Department of Obstetrics and Gynecology, 60202Antwerp University Hospital, Antwerp, Belgium.
Marc PeetersDepartment of Oncology, 60202Antwerp University Hospital Antwerp, Antwerp, Belgium.
Antwerp University Hospital · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has overwhelmed the capacity of healthcare systems worldwide. Cancer patients, in particular, are vulnerable and oncology departments drastically needed to modify their care systems and established new priorities. We evaluated the impact of SARS-CoV-2 on the activity of a single cancer center.

methodsWe performed a retrospective analysis of (i) volumes of oncological activities (2020 vs 2019), (ii) patients' perception rate of the preventive measures, (iii) patients' SARS-CoV-2 infections, clinical signs thereof, and (iv) new diagnoses made during the SARS-CoV-2 pandemic.

resultsAs compared with a similar time frame in 2019, the overall activity in total numbers of outpatient chemotherapy administrations and specialist visits was not statistically different (

conclusionsThis retrospective cohort analysis adds to the evidence that continuation of active cancer therapy and specialist visits is feasible and safe with the implementation of telemedicine. These data further confirm the impact of SARS-CoV-2 on cancer care management, cancer diagnosis, and impact of infection on cancer patients.

Indexed as

Age FactorsCancer Care FacilitiesComorbidityCOVID-19CyclopentanesHumansInfection ControlNeoplasmsOrganosilicon CompoundsPandemicsPerceptionRetrospective StudiesSARS-CoV-22,2-dimethyl-4-(chloromethyl)-1,3-dioxa-2-silacyclopentaneCyclopentanesOrganosilicon Compoundscancer careCOVID-19e-healthSARS-CoV-2telehealth

Identifiers

PMID34623943
PMCPMC8504214
OpenAlexW3144724552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.